4Forner A, Llovet JM, BmixJ. Hepatocellular carcinoma[J]. Lancet, 2012, 379(9822):1245-1255.
5Wu CY, Chen YJ, Ho HJ, et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection[J]. JAMA, 2012, 308(18): 1906-1914.
6Chan AC, Chok KS, Yuen WK, et al. Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma[J]. Arch Surg, 2011, 146(6): 675-681.
7Piao CY, Fujioka S, Iwasaki Y, et al. Lamivudine treatment in patients with HBV-related hepatocellular carcinoma-using an un- treated, matched control cohort[J]. Acta Med Okayama, 2005, 59 (5) :217-224.
8Kuzuya T, Katano Y, Kumada T, et al. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2007, 22(11): 1929-1935.
9Wong JS, Wong GL, Tsoi KK, et al. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treat- ment of chronic hepatitis B-related hepatocellular carcinoma[J]. Aliment Pharm Ther, 2011, 33(10):1104-1112.
10Zhong JH, Li LQ Wu LC. Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma[J]. Cochrane Database Syst Rev, 2011, 12:CD008713.
